Linagliptin/Metformin Stada (Metformin Hydrochloride, Linagliptin)

Linagliptin/Metformin is indicated for the management of type 2 diabetes mellitus, providing a combined therapeutic approach to improve glycaemic control.

• Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels.
• Inadequate control on metformin alone: adds DPP‑4 inhibition to achieve target HbA1c.
• Combination therapy with insulin: reduces required insulin dose and risk of hyperglycaemia.
• Adjunct to lifestyle modification: supports diet and exercise in achieving glucose targets.
• Patients with moderate renal impairment: provides glycaemic control without dose adjustment of linagliptin.
• Fixed‑dose combination therapy: simplifies regimen and improves adherence.

• Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which prevents the breakdown of the incretin hormones GLP‑1 and GIP, thereby enhancing glucose‑dependent insulin secretion and suppressing glucagon release. Metformin hydrochloride reduces hepatic gluconeogenesis, increases peripheral insulin sensitivity, and promotes glucose uptake in muscle, collectively lowering plasma glucose concentrations. These complementary mechanisms provide additive glucose‑lowering effects without significant risk of hypoglycaemia when used as monotherapy.

The combination of linagliptin and metformin may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects

• Gastrointestinal upset: nausea, abdominal discomfort, or flatulence.
• Diarrhoea: loose stools, especially early in therapy.
• Headache: mild to moderate intensity.

Serious or Rare Side Effects

• Lactic acidosis: rare but potentially fatal metabolic disturbance.
• Pancreatitis: severe abdominal pain with elevated pancreatic enzymes.
• Severe hypoglycaemia: risk increases when combined with insulin or sulfonylureas.

When prescribing linagliptin/metformin, clinicians should consider several precautionary measures to ensure safe use.

• Renal function assessment: evaluate eGFR before initiating and periodically thereafter.
• Hepatic function monitoring: check liver enzymes in patients with liver disease.
• Cardiovascular risk: use cautiously in patients with heart failure.
• Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks.
• Drug interaction review: assess concomitant medications that may affect metformin clearance.
• Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Linagliptin/metformin may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Concomitant insulin or sulfonylureas: may cause hypoglycaemia.
• Iodinated contrast agents in renal impairment: risk of acute kidney injury.
• Cimetidine: can increase metformin plasma concentrations.
• High‑dose alcohol: raises risk of lactic acidosis.
• Duplicate DPP‑4 inhibition: using another DPP‑4 inhibitor adds no benefit.

Moderate Interactions (Monitor Closely)

• NSAIDs: may affect renal function and metformin excretion.
• Diuretics: can reduce renal clearance of metformin.
• ACE inhibitors or ARBs: monitor renal function when combined.
• Beta‑blockers: may mask hypoglycaemia symptoms.
• Rifampin: may lower linagliptin plasma levels.